Saxenda Pen (Liraglutide) Injection

What is Saxenda®?

Saxenda® contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved for weight management and must be prescribed by a qualified healthcare professional. The medicine is supplied in prefilled pens at a concentration of 6 mg/mL. Each pack contains five prefilled pens.

Treatment should be used alongside a reduced-calorie diet and increased physical activity, in line with guidance from recognised authorities such as NICE guidance on obesity management.

Who is Eligible for Saxenda® Treatment?

Saxenda may be prescribed for adults who meet one of the following criteria:

• A body mass index (BMI) of 30 kg/m² or higher (obesity).
• A BMI of 27 kg/m² or higher (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidaemia.

A full medical assessment is required before initiating therapy.

How Saxenda® Works

Liraglutide mimics the natural GLP-1 hormone, which regulates appetite and food intake. By acting on appetite centres in the brain, Saxenda increases feelings of fullness and reduces hunger, helping patients consume fewer calories.

This mechanism supports gradual and sustainable weight reduction when combined with lifestyle modification.

Clinical Evidence and Expected Results

Clinical studies lasting 56 weeks demonstrated that patients treated with Saxenda achieved greater average weight loss compared with placebo alongside diet and exercise. In one study involving individuals with a BMI of 38, participants using liraglutide lost an average of 17.3 pounds, compared with approximately 7 pounds in the placebo group.

Individual results vary depending on adherence, diet, activity levels, and metabolic factors.

Who Should Not Use Saxenda®

• Patients with a personal or family history of medullary thyroid carcinoma (MTC).
• Individuals diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Those with type 1 diabetes or diabetic ketoacidosis.

Important Safety Information

• Be alert for symptoms suggestive of thyroid tumours.
• Seek urgent medical advice if severe abdominal pain suggests pancreatitis.
• Monitor for possible gallbladder disease or increased heart rate.
• Persistent vomiting or severe abdominal discomfort requires immediate assessment.

For comprehensive prescribing details, consult official regulatory resources such as the European Medicines Agency (EMA) or MHRA.

Common Side Effects

• Nausea
• Diarrhoea
• Constipation
• Reduced appetite
• Injection-site reactions (redness or itching)

Dosing and Administration

Initial Dose

Begin with 0.6 mg once daily for one week to allow gastrointestinal tolerance.

Dose Escalation Schedule

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5 onwards: 3.0 mg daily (maintenance dose)

Maintenance Dose

Continue 3.0 mg once daily as prescribed.

Missed Dose

Do not administer an additional dose. If more than three days have elapsed since the last injection, restart at 0.6 mg and follow the titration schedule again.

How to Inject Saxenda®

• Inject once daily at any convenient time, with or without food.
• Administer subcutaneously into the abdomen, thigh, or upper arm.
• Rotate injection sites to reduce skin irritation.
• Pens do not include needles; compatible pen needles are required.

Storage Instructions

• Store unused pens in a refrigerator.
• After first use, store at room temperature or refrigerated for up to 30 days.
• Protect from excessive heat and direct light.

When to Discontinue Treatment

If at least 5% of baseline body weight has not been lost after 12 weeks on the 3.0 mg daily dose, discontinuation may be recommended following clinical review.

Purchasing Saxenda®

Saxenda is available through licensed pharmacies. Some patients choose to order online for convenience and competitive pricing. A valid prescription is required. International shipping and multiple payment options may be available depending on the supplier.

Frequently Asked Questions

Is Saxenda® a GLP-1 medication?

Yes. Saxenda belongs to the GLP-1 receptor agonist class, which regulates appetite and calorie intake.

Is Saxenda® the same as Ozempic®?

No. Although both are GLP-1 receptor agonists, Saxenda is licensed for weight management, whereas Ozempic is primarily indicated for type 2 diabetes.

How much weight can be lost?

Weight reduction varies, but some individuals lose 1–2 pounds per week during early treatment when combined with lifestyle modification.

How many pens are required for four weeks?

Typically, five pens are required during the first month due to dose escalation.